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Background: Despite therapeutic advances in targeted therapy, metastatic renal cell carcinoma (RCC) remains
incurable for the vast majority of patients. Key molecular events in the pathogenesis of RCC include inactivation of
the VHL tumour suppressor gene (TSG), inactivation of chromosome 3p TSGs implicated in chromatin modification
and remodelling and de novo tumour-specific promoter methylation of renal TSGs. In the light of these
observations it can be proposed that, as in some haematological malignancies, demethylating agents such as
azacitidine might be beneficial for the treatment of advanced RCC.
Results: Here we report that the treatment of RCC cell lines with azacitidine suppressed cell proliferation in all 15
lines tested. A marked response to azacitidine therapy (>50% reduction in colony formation assay) was detected in
the three cell lines with VHL promoter methylation but some RCC cell lines without VHL TSG methylation also
demonstrated a similar response suggesting that multiple methylated TSGs might determine the response to
demethylating therapies. To identify novel candidate methylated TSGs implicated in RCC we undertook a combined
analysis of copy number and CpG methylation array data. Candidate novel epigenetically inactivated TSGs were
further prioritised by expression analysis of RCC cell lines pre and post-azacitidine therapy and comparative
expression analysis of tumour/normal pairs. Thus, with subsequent investigation two candidate genes were found
to be methylated in more than 25% of our series and in the TCGA methylation dataset for 199 RCC samples: RGS7
(25.6% and 35.2% of tumours respectively) and NEFM in (25.6% and 30.2%). In addition three candidate genes were
methylated in >10% of both datasets (TMEM74 (15.4% and 14.6%), GCM2 (41.0% and 14.6%) and AEBP1 (30.8% and
13.1%)). Methylation of GCM2 (P = 0.0324), NEFM (P = 0.0024) and RGS7 (P = 0.0067) was associated with prognosis.
Conclusions: These findings provide preclinical evidence that treatment with demethylating agents such as
azacitidine might be useful for the treatment of advanced RCC and further insights into the role of epigenetic
changes in the pathogenesis of RCC.
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Aberrant DNA methylation, in particular promoter
hypermethylation and transcriptional silencing of tumour
suppressor genes (TSGs), has an important role in the de-
velopment of many human cancers including renal cell
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reproduction in any medium, provided the orof all cancers and is diagnosed in >200,000 individuals in
the world each year [1-3]. Most RCC cases (approximately
75%) are classified as clear-cell (conventional) RCC
(cRCC), and the most common genetic event in the evolu-
tion of sporadic cRCC is inactivation (by mutation, allele
loss or promoter methylation) of the von Hippel-Lindau
(VHL) TSG [4-7]. VHL inactivation leads to stabilization
of the hypoxia-inducible transcription factors (HIF)-1 and
HIF-2 and activation of a wide repertoire of hypoxia re-
sponse genes [8,9]. Although the VHL mutations in pri-
mary clear-cell RCC were first described 20 years ago,
until recently, attempts to identify other frequently
mutated RCC genes had generally been disappointing.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sequencing and exome re-sequencing strategies to
sporadic RCC has led to the identification of several
frequently mutated TSGs. Thus, mutations in PBRM1,
which encodes a chromatin remodeling complex sub-
unit, were detected in approximately 40% of RCC [10]
and mutations in genes for other chromatin modifiers
have also been described, such as SETD2, KDM6A/
UTX and BAP1 [11-13]. In addition, we and others
have sought to investigate the role of de novo TSG pro-
moter hypermethylation in the pathogenesis of RCC
and evidence for tumour-specific promoter region
hypermethylation has been reported for >60 candidate
TSGs (see [2] and references within). Notably, certain
important TSGs (for example, RASSF1A) are frequently
methylated but infrequently mutated [14,15].
There are no curative therapies for metastatic RCC
and an important rationale for cancer genomic and
epigenomic studies is to provide a basis for the devel-
opment of novel therapies for advanced disease. The
identification of frequently mutated and methylated
RCC TSGs could highlight critical pathways that might
be targeted for therapeutic intervention but, if de novo
promoter methylation of candidate RCC TSGs plays a
significant part in renal oncogenesis, it can be proposed
that reversal of promoter methylation would reduce
RCC cell proliferation. Demethylating agents such as
azacitidine (5-aza-cytidine/Vidaza) and decitabine (5-aza-
2’-deoxycytidine/Dacogen) have been used with some
success to treat myelodysplastic syndrome and acute mye-
logenous leukaemia [16] and are being investigated for the
treatment of solid tumours (for example, of the breast and
colon) [17].
Given the key role of the VHL TSG inactivation in
RCC we investigated whether the response of RCC cell
lines to treatment with the demethylating agent
azacitidine was dependent on VHL methylation status.
We found that azacitidine treatment suppressed the
growth of RCC cell lines but the response to azacitidine
was not restricted to VHL methylated cell lines, and so
to identify novel epigenetically inactivated candidate
TSGs for RCC we proceeded to analyse the results of
combined copy number and methylation profiling on
primary RCC tumours, and investigate whether methyla-
tion of such genes was associated with survival.
Results
In vitro dose-response relationships for azacitidine
treatment and promoter region hypermethylation
To determine the effects of treatment with escalating
doses of azacitidine (control, 0.3 μM, 1 μM, 3 μM) on
in vitro cell growth, colony formation assays were under-
taken with fifteen RCC cell lines (three with VHL pro-
moter region methylation (SKRC54, 769-P and A704)).After initial optimisation experiments, cells were seeded
at 1 in 2,000 dilution and maintained in DMEM and
10% fetal bovine serum; surviving colonies were counted
14 to 21 days after initial seeding.
The results of the colony formation assays are
displayed in Figure 1. Compared to controls, treatment
with 3 μM azacitidine reduced the number of colonies
formed in each cell line to varying degrees ranging from
>90% reduction in 769-P to <20% reduction in CAL54.
However the sensitivity to lower doses of azacitidine was
variable with some cell lines demonstrating no effects at
the lowest 0.3 μM azacitidine doses (for example, 786-O,
SKRC45, RCC4 and RCC11), while four cell lines,
SKRC18, A704, 796-P and A498, demonstrated a 50% or
greater reduction at both 1 μM and 3 μM azacitidine.Effect of azacitidine on anchorage-independent growth of
RCC cell lines
The effect of 3 μM azacitidine on anchorage-independent
growth of seven RCC cell lines was assessed in soft agar
assays (the remaining cell lines did not grow in soft agar).
In all cases treatment with 3 μM azacitidine reduced
anchorage-independent growth (as assessed by number of
colonies >100 μm) (Figure 2A and B). The median reduc-
tion (relative to control) in number of colonies was 49.7%
(range 27.6 to 96.9%). The only cell line from the four
most azacitidine-sensitive lines that could be assessed,
769-P also demonstrated the greatest degree of reduction.Relationship between CpG methylation profiling of
human cancer genes and RCC cell line growth response
to azacitidine treatment
The Illumina GoldenGate Methylation Cancer Panel I
array provides quantitative CpG methylation data at
1,505 individual CpG dinucleotides associated with 807
human genes (with enrichment for candidate TSGs
methylated in human cancers). In order to profile pat-
terns of RCC-specific candidate TSG methylation after
excluding genes methylated in normal kidney tissue (in-
cluding X-chromosome genes), cluster analysis was
performed to group the RCC cell lines according to
methylation profiling results (see Figure 2C). This pro-
duced two major clusters. The first cluster contained five
cell lines and included three of the four of the most
azacitidine-sensitive lines (SKRC18, A704 and A498, but
not 769-P (Figure 2C, grey boxes)), though the other two
lines in this cluster, CAKI-2 and RCC11, demonstrated
much milder responses to azacitidine. The three cell lines
with the greatest (>50%) reduction in anchorage-
independent colony formation, SKRC45, CAKI-1 and
769-P were in the second major cluster and apparently did
not demonstrate a strong hypermethylation phenotype
(Figure 2C, red boxes).
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Figure 1 Azacitidine treatment and growth of renal cell carcinoma (RCC) cell lines. Effects of escalating doses of azacitidine on colony
formation (absolute numbers of colonies) for 15 RCC cell lines. Treatment with 3 μM azacitidine reduced the colony-forming potential of all RCC
cell lines. However, at lower doses the effect varies markedly between cell lines.
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sporadic primary RCCs
Copy number analysis of 46 primary sporadic RCCs
demonstrated multiple regions of chromosomal abnor-
mality in the tumour genomes. Large-scale deletions of
statistical significance were observed at 1p/1q, 3p, 6p/6q,
8p, 9p/9q and 14q, and large-scale amplifications/dupli-
cations of statistical significance were observed at 5p/5q,
7p/7q, 8q and 20p/20q (Figure 3). These results were
largely in agreement with previous similar studies that
had highlighted chromosomal deletions at 3p, 14p, 8p,
6q, 9p and 4p [18], and losses in these regions occurred
at 74, 36, 24, 20, 19 and 13% of tumours respectively,
whereas previously published chromosomal amplifica-
tions/duplications include 5q and 7 and these occurred
in 43 and 26% of cases respectively (Additional file 1:
Table S1).
In any given tumour a gene could be inactivated or
lost by either copy number alterations, promoter methy-
lation, somatic mutation or a combination of these fac-
tors and others. It is reasonable to hypothesize that
genes that reside within areas of copy number variation
and are frequently methylated may represent genes with
important roles in tumourigenesis. In this study these
were considered two independent mechanisms and were
not assessed in combination. Thus, to identify genes
demonstrating frequent tumour-specific promoter re-
gion methylation (using criteria of six or more tumours
with β-values ≥0.33 and β-values <0.25 in all nine nor-
mal samples) that mapped within the previously de-
scribed statistically significant regions of copy number
abnormalities, we reanalysed the results of tumour CpG
methylation profiling using the Illumina Infinium
HumanMethylation27 array [19]. There were 126 genesthat satisfied the selection criteria: 72 mapped within the
common chromosome deletion regions (1p/1q (n = 24),
3p (n = 5), 6p/6q (n = 23), 8p (n = 4), 9p/9q (n = 5)
and 14q (n = 11) and 54 to the common amplified/du-
plicated chromosome regions (5p/5q (n = 18), 7p/7q
(n = 16), 8q (n = 11) and 20p/20q (n = 11) (Figures 4A
and 5A, and Additional file 2: Figures S1A-D and
Additional file 3: Figure S2A-B). Four genes (DLEC1,
COL1A2, FBN2 and TNFRSF10C) that satisfied the se-
lection criteria were investigated in our previous study
[19] and thus removed from this study.
To prioritise the 122 candidate novel methylated genes
for further investigation we interrogated our previously
reported data on gene expression post 5-aza-cytidine
treatment in RCC cell lines [2] and identified those
candidate methylated genes whose expression was
upregulated after 5-aza-cytidine treatment, at least 8-
fold in two cell lines or ≥8-fold in one cell line and ≥4-
fold in at least another two cell lines. This refined the
candidate gene list down to 37 genes: 19 genes on the
deleted chromosomes (1p/1q (n = 9), 6p/6q (n = 3), 8p
(n = 2), 9p/9q (n = 1) and 14q (n = 4)) and 18 genes on
the amplified/duplicated chromosomes (5p/5q (n = 7),
7p/7q (n = 4), 8q (n = 4) and 20p/20q (n = 3))
(Figures 4A and 5A, and Additional file 2: Figure S1A-D
and Additional file 3: Figure S2A-B). To determine
whether tumour-specific promoter methylation was
associated with suppression of gene expression in pri-
mary tumours, RT-PCR was performed on 15 tumours
and their associated normal pairs for the 37 genes
selected for further investigation. Five genes demon-
strated complete loss or downregulation of expression in
at least 20% of RCC tumours (GCM2 (80% of RCC),
RGS7 (46.7%), TMEM74 (46.7%), NEFM (20%) and
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Figure 2 Azacitidine treatment reduces the anchorage independent growth of renal cell carcinoma (RCC) cell lines. (A) Pre-treatment
with 3 μM azacitidine resulted in reduction of anchorage-independent growth in all seven RCC cell lines tested. Other cell lines did not grow
suspended in agar. Error bars represent standard error. (B) Representative images (6 weeks after seeding in agar) of control colonies and colonies
formed after azacitidine pre-treatment. (C) Illumina GoldenGate Methylation Cancer Panel I Beadarray cluster analysis results of RCC cell lines. The
four cell lines, SKRC18, A704, 796-P and A498 that demonstrated a 50% or greater colony reduction at both 1 μM and 3 μM azacitidine doses are
highlighted with grey boxes. The three cell lines with the greatest (>50%) reduction in anchorage-independent colony formation, SKRC45, CAKI-1
and 769-P, are highlighted with red boxes.
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RGS7 and NEFM were located in regions of deletion and
TMEM74 and AEBP1 in copy number gain regions
(Table 1, Figures 4A and 5A, and Additional file 2:
Figure S1A,C and Additional file 3: Figure S2B).To replicate these findings we investigated whether
the five candidate methylated genes (GCM2, RGS7,
TMEM74, NEFM and AEBP1) were also methylated in
the 199 tumour and normal pairs analysed on the same
platform (Illumina HumanMethylation27 array) by the
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Figure 3 Copy number analysis. Genetic identification of significant targets in cancer (GISTIC) analysis of the Affymetrix SNP6.0 data for 46
sporadic renal cell carcinoma (RCC) tumours, highlighting the large regions of chromosomes that were either deleted or amplified/duplicated
to a significant degree. Smaller specific regions of loss or gain are highlighted to the right of each analysis.
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carcinoma (KIRC) project. A difference in β-value of
0.3 or greater between tumour and normal tissue was
taken to represent a significant increase in methylation.
In the TCGA data the frequency of methylation for
RGS7 was 35.2% (Birmingham series methylation fre-
quency = 25.6%), for NEFM it was 30.2% (versus 25.6%),
for TMEM74 it was 14.6% (15.4%), for GCM2 it was
14.6% (versus 41%) and for AEBP1 it was 13.1% (30.8%)
(Figure 6 and Additional file 4: Figure S3). Clinical data
were available for most (193/199) of the TCGA samples
and we therefore investigated whether the methylation
status of GCM2, RGS7, TMEM74, NEFM and AEBP1
correlated with clinical characteristics (Additional file 5:
Table S2). Methylation at GCM2 (P = 0.0324), NEF3/
NEFM (P = 0.0024) or RGS7 (P = 0.0067) wassignificantly associated with survival (Figure 7A and
Additional file 6: Figure S4). The combined effect of the
presence of methylation in all genes demonstrated a
better association with survival (P <0.0001) and the
combination of any two also being significantly associ-
ated (P = 0.0027) (Figure 7B).
Discussion
Demethylating agents such as azacitidine or decitabine
have been used successfully for the treatment of haem-
atological neoplasias, such as acute myeloid leukaemia,
chronic myelomonocytic leukaemia (CMML) and the
preleukaemic disorder myelodysplastic syndrome [16].
Additionally, usage of these demethylating agents is be-
ing extended to solid tumours in clinical trials and the
National Institutes of Health (NIH) currently have active
AB
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Figure 4 Analysis of the deleted chromosomes. (A) Schematic of the deleted chromosome 8p. The methylation levels for the selected genes
in the 38 sporadic renal cell carcinomas (RCCs) are represented by green ovals for no significant methylation or yellow (β-values ≥0.33) and red
(β-values ≥0.4) ovals for positive levels of hypermethylation. The methylation levels for the nine normal kidneys are represented by green ovals
for no methylation (β-values <0.25). The degree of re-expression after 5′-aza treatment in the 11 RCC cell lines is represented by green ovals for
no significant increase/change or yellow ovals for a positive increase (4-fold or greater) and red ovals for a highly positive increase (8-fold or
greater). Other genes of interest were mapped to the chromosome with black arrows representing known hypermethylated RCC-associated
genes and blue arrows representing genes known to be mutated in RCC. (B) Example reverse-transcription (RT)-PCR analysis of the tumour/
associated kidney normal pairs for the positive selected genes from chromosomes 1, 6 and 8p. Each pair for each gene is shown with the tumour
result on the left and the associated normal on the right and with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) band to demonstrate
loading. Generally, the loading was skewed so that more tumour cDNA was analysed than the associated normal cDNA to emphasise that any
loss observed was real and significant. In all cases at least one pair was shown where no loss/decrease was observed, to demonstrate the mRNA
would normally be expressed in the tumour tissue.
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squamous cell head and neck cancer, and for decitabine
in ovarian cancer and melanoma (http://clinicaltrials.
gov). Currently, epigenetic abnormalities are being
recognised as a prominent feature of RCC. Thus, muta-
tions in genes implicated in chromatin remodelling and
modification such as PBRM1, SETD1, KDM6A/UTX and
BAP1 have recently been shown to be frequently found
in RCC [10-13] and more than 60 candidate TSGs have
been reported to demonstrate promotor region methyla-
tion in RCC [2] (and references within). In our in vitro
studies of RCC cell lines we found that treatment with
azacitidine reduced cell growth, in both colony forma-
tion assays and soft agar assays, in all cell lines tested.
These findings are consistent with two previous studies
in RCC cell lines. Thus Alleman et al. [20] treated four
RCC cell lines (with promoter methylation and loss of
expression of VHL) with 5-aza-2′-deoxycytidine and
demonstrated re-expression of VHL and reduced size ofxenografted tumours. In addition, Negrotto et al. [21]
reported that non-cytotoxic doses of decitabine adminis-
tered to four RCC cell lines (SKRC29, SKRC45, ACHN
and RENCA) decreased proliferation of RCC cells (in
in vitro and in vivo assays) but not normal kidney epi-
thelial cells. In our studies the reduction in cell growth
was variable with some cell lines showing reduction at
lower doses and marked variations in relative response
(compared to untreated growth) to 1 μM and 3 μM
azacitidine. Each of the cell lines with VHL TSG pro-
moter methylation demonstrated a marked (>50%) re-
duction in growth in the colony formation but an
association between VHL methylation and response to
azacitidine was not statistically significant (P = 0.077).
Given the critical role of VHL inactivation in RCC, a
marked response to demethylating therapy in cell lines
with VHL hypermethylation might not appear unex-
pected, and indeed, preferential effects of 5-aza-2′-
deoxycytidine treatment of VHL-methylated versus
AC
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Figure 5 Analysis of the amplified/duplicated chromosomes. (A) Schematic of the amplified/duplicated chromosome 8q. The methylation
levels for the selected genes in the 38 sporadic renal cell carcinomas (RCCs) are represented by green ovals for no significant methylation or
yellow (β-values ≥0.33) and red (β-values ≥0.4) ovals for positive levels of hypermethylation. The methylation levels for the nine normal kidneys
are represented by green ovals for no methylation (β-values <0.25). The degree of re-expression after 5′-aza treatment in the 11 RCC cell lines is
represented by green ovals for no significant increase/change or yellow ovals for a positive increase (4-fold or greater) and red ovals for a highly
positive increase (8-fold or greater). Other genes of interest were mapped to the chromosome, with red arrows representing oncogenes, black
arrows representing known hypermethylated RCC-associated genes and blue arrows representing genes known to be mutated in RCC. The blue
star indicates the gene is both mutated and hypermethylated. (B) Example reverse transcription (RT)-PCR analysis of the tumour/associated
kidney normal pairs for all the selected genes for chromosome 8q and (C) the positive gene on chromosome 7. Each pair for each gene is
shown with the tumour result on the left and the associated normal on the right and with a glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) band to demonstrate loading. Generally, the loading was skewed so that more tumour cDNA was analysed than the associated normal
cDNA to emphasise that any loss observed was real and significant. In all cases at least one pair was shown where no loss/decrease was
observed to demonstrate the mRNA would normally be expressed in the tumour tissue.
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Table 1 RT-PCR analysis for selected genes in chromosomal regions of deletion or amplification/duplication in primary
RCC tumours and associated normal tissue
Deletions
Chromosome Potential tumour specifically inactivated genes
Tum Exp. Lost/Tum. Exp. Down-regulated/Tum. Exp. Normal or Up-regulated (Percentage of lost/down-regulated)
Chromosome 1 CHD5 TNFRSF1B KIF17 UQCRH GPX7
0/1/14 (6.7%) 0/0/15 (0.0%) 0/0/15 (0.0%) 0/0/15 (0.0%) 0/0/15 (0.0%)
TTC22 PDE4DIP RGS7 TRIM58
1/1/13 (13.3%) 0/0/15 (0.0%) 3/4/8 (46.7%) 0/2/13 (13.1%)
Chromosome 6 GCM2 HIST1H3G HIST1H4H
8/0/2 (80.0%) 0/0/15 (0.0%) 0/0/15 (0.0%)
Chromosome 8p GATA4 NEFM
1/0/8 (11.1%) 1/2/12 (20.0%)
Chromosome 14q EFS PTGDR C14orf39 FLRT2
0/1/14 (6.7%) 0/1/14 (6.7%) 1/0/8 (11.1%) 0/1/14 (6.7%)
Amplifications
Chromosome Potential tumour specifically inactivated genes
(Percentage of tumours in which gene expression is lost or down-regulated in brackets)
Chromosome 1 TWIST1 HOXA11 AEBP1 KLF14
1/0/13 (7.1%)1 0/2/13 (13.3%) 3/0/12 (20.0%) 0/2/13 (13.3%)
Chromosome 8p SOX17 CA3 ANGPT1 TMEM74
0/2/13 (13.3%) 0/3/12 (20.0%) 0/0/15 (0.0%) 4/3/8 (46.7%)
1Key= Tumour Expression Lost/Tumour Expression Down-regulated/Tumour Expression Normal or Up-regulated (Percentage of lost/down-regulated).
Genes in bold type (GCM2, RGS7 and NEFM) demonstrated complete loss or downregulation of expression in at least 20% of RCC tumours and were located in
regions of deletion.
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in vivo studies [20]. However, previously re-expression of
pVHL in VHL-inactivated RCC cells has been reported to
suppress growth in in vivo but not in vitro assays [22,23]. It
is possible that the better response in VHL-methylated cell
lines might be because VHL-methyation is a marker for
other critical epigenetic changes that are reversed by treat-
ment with azacitidine. However, there were no apparent
clear correlations between response to azacitidine and the
grouping of RCC cell lines according to their methylation
array profiles (although this only represents a subset of
CpGs) or cell-line population doubling-time.
In order to expand the catalogue of frequently methyl-
ated candidate TSGs in RCC we undertook an analysis
of copy number and CpG methylation profiling of spor-
adic RCC. Previously we reported an analysis of the CpG
methylation analysis data [19] but for this reanalysis we
concentrated on the methylation status of genes within
regions that demonstrated copy number abnormalities.
One caveat to this methodology is the interpretation of
deletions or amplifications at centromeric and telomeric
regions where enrichment for variable non-tandem re-
peats have been shown to harbour hotspots of natural
variation in the normal population [24-26]. For this
study we only considered large, common deletions oramplifications that had been previously observed rather
than smaller focal alterations to avoid this. When hunt-
ing for novel TSGs, chromosomal regions that demon-
strate copy number loss in cancer have traditionally
been prioritised, whereas regions of copy number gain
are highlighted in the search for proto-oncogenes. How-
ever, we decided to focus on both regions of copy num-
ber gain and loss, as we reasoned that if a region of copy
number gain provided a growth advantage for a cancer
cell there might need to be concurrent inactivation of
TSGs within that region of amplification to gain the full
benefit. Indeed, two of the five novel candidate TSGs
(TMEM74 and AEBP1) that we focused on mapped
within regions of copy number gain. These five genes
represent a diversity of functions. AEBP1 (the adipocyte
enhancer binding protein 1) is a transcriptional repres-
sor with carboxypeptidase (CP) activity. AEBP1 may
regulate mitogen-activated protein (MAP)-kinase activity
and has been reported to be methylated in rat prostate
cancer lines [27]. GCM2 is homologous to the Drosoph-
ila glial cells missing gene and encodes a transcription
factor implicated in parathyroid gland development, and
mutations in GCM2 have been reported in familial
hypoparathyroidism [28,29]. NEFM encodes the medium
neurofilament protein and has been reported previously
Figure 6 Assessment of selected methylated Infinium Methylation27 probes in the Cancer Genome Atlas (TCGA) tumour and
associated normal pairs. These in-scale diagrams map the position of the Infinium Methylation27 microarray probes for three of the five
selected genes, GCM2, RGS7, NEFM, in relation to their CpG island and first exon(s). The probes selected for by this analysis are coloured red. For
each probe there is a graph of the average β-values for both the tumour and the associated normal with the 199 tumour/associated normal
TCGA samples split into those designated methylated or unmethylated. Methylated samples were defined as having an increase in β-value of 0.3
or greater within the tumour compared to the associated normal. The number and percentage of methylated and unmethylated samples are
shown, with those demonstrating significant tumour-specific methylation coloured in red.
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[30,31]. The regulator of G-protein signalling (RGS)
pathway has been reported to play a role in signalling
transduction and carcinogenesis and a RGS7 single
nucleotide polymorphism (SNP) has previously been
reported to be associated with survival in non-small cell
lung cancer patients treated with chemoradiotherapy
[32]. TMEM74 is known to regulate autophagy and
though it has not been implicated previously in RCC, it
is interesting to note that the tumour suppressor activity
of the VHL TSG has been linked to regulation of au-
tophagy [33-35].
A feature of the present study is that we were able to
corroborate our CpG methylation profiling results withthose generated by the TCGA on the same platform.
However, though the direct assay of CpG methylation fa-
cilitates the identification of possible epigenetically
inactivated TSGs, we have demonstrated previously that
this strategy is not entirely specific as some genes with
apparent tumour-specific methylation are not confirmed
on further analysis [19]. Hence, it is necessary to com-
bine, as in the current study, high-throughput methy-
lation profiling assays with confirmatory assays and
investigations to confirm transcriptional silencing. Ha-
ving pursued such investigations we were able, in the
knowledge that the probes used to detect methylation
were accurate, utilise the TCGA data to look for
correlations between gene-specific methylation and
Figure 7 Kaplan-Meier survival curves for the Cancer Genome Atlas (TCGA) samples dependent on the methylation of the selected
gene probes. (A) These Kaplan-Meier survival curves demonstrate the difference in survival between methylated and unmethylated tumours for
individual gene probes for GCM2, NEFM and RGS7. (B) These Kaplan-Meier survival curves demonstrate the difference in survival between
methylated and unmethylated tumours for methylation of all three or two or more of these genes (B).
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survival and methylation at GCM2, NEFM and RGS7.
De novo tumour-specific promoter methylation repre-
sents an attractive target for developing biomarkers,
as methylated tumour DNA can be detected in plasma
and urine [36,37] and the methodology to detect CpG
promoter TSG methylation is more straightforward
than that required to detect the wide variety of in-
activating mutations that usually occur in TSGs.
Hence, the identification of methylated candidate
TSGs that are associated with prognosis will facilitate
the development of a repertoire of biomarkers that
might be used to stratify RCC into tumours with
good or poor prognosis.Conclusions
Previously we and others have reported evidence that
the frequency of TSG methylation is not equally distrib-
uted across RCC and that a subset of tumours may
manifest high levels of TSG methylation [19,38,39].
We did not find a correlation between the methylation
profile of RCC cells lines and response to epigenetic
therapy but it could be that more comprehensive methy-
lation profiling is required to uncover such an effect. Al-
ternatively it could be that therapeutic response to
demethylating agents is determined by the methylation
status of a number of key genes. Given the large number
of candidate TSGs reported to be methylated in RCC
and the relatively small number of available RCC cell
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key genes whose methylation status could predict re-
sponse to epigenetic therapies. Our results suggest that
epigenetic therapies might provide an additional treat-
ment option for metastatic RCC that is unresponsive to
standard management options. In order to develop pre-
dictors of likely response to epigenetic therapies in RCC
it is important that whenever possible, data on the
methylation status of renal TSGs (for example,VHL) are
collected on patients with advanced RCC who receive
such therapy.
Methods
RCC cell lines, tumours and azacitidine treatment
Fifteen RCC cell lines (SKRC18, SKRC39, SKRC45,
SKRC47, SKRC54, RCC4, RCC11, 786-O, 796-P, A704,
A498, KTCL26, CAL54, CAKI-1 and CAKI-2) were
maintained in DMEM (Invitrogen, San Diego, CA, USA)
supplemented with 10% FCS at 37°C, and 5% CO2. The
demethylating agent azacitidine was freshly prepared in
ddH2O and filter-sterilized.
DNA was extracted from sporadic RCC as described
previously [19]. All participants gave informed written
consent for research studies and the study was conducted
according to the principles expressed in the Declaration of
Helsinki and was approved by the relevant Institutional
Review Board/Ethics committees. RNA was extracted for
15 patients where sufficient matched RCC tumour and
normal tissue was available. Total RNA was isolated from
both using RNA-Bee reagent following the manufacturer’s
instructions (AMS Biotechnology, Oxford, UK), followed
by purification using RNeasy Mini-columns (Qiagen,
Crawley, UK).
In vitro assessment of RCC cell line growth
The effect of azacitidine treatment on RCC cell line
growth in vitro was assessed by colony formation and
soft agar assays.
Colony formation assay
Cell lines were plated in 75-cm2 flasks in DMEM
supplemented with 10% FCS at differing densities, de-
pending upon their replication factor, to ensure that both
control and azacitidine-treated lines reached approxi-
mately 75% confluency at the point of cell counting.
Twenty-four hours later, cells were treated with 0.3 μM,
1 μM and 3 μM azacitidine. Subsequent treatments of
azacitidine were performed every 24 hours until cells had
undergone 72 hours of treatment. After 72 hours treat-
ment with 0.3 μM, 1 μM and 3 μM azacitidine compound,
cells were trypsinised and counted. Serial dilutions
of 1/500, 1/1,000 and 1/,000 were made from an ini-
tial stock of 1×10 [6] treated cells. Cells were seeded
into 100-mm tissue-culture dishes and maintained inDMEM and 10% fetal bovine serum. Surviving colonies
were stained with 0.4% crystal violet (Sigma) in 50%
methanol, 14 to 21 days after initial seeding, and counted.
Cells not used in the colony formation assay were snap-
frozen in liquid nitrogen for subsequent DNA (Roche,
Mannheim, Germany) and RNA (Geneflow, Lichfield,
United Kingdom) extraction.
Soft agar assay
After treatment with 3 μM azacitidine (as for colony
formation assay) cells were seeded into 2 ml DMEM in
10% FCS and 3% agar. Cells were maintained by
addition of 200 μl of DMEM in 10% FCS weekly. After
6 weeks of growth, a final count of colonies (>100 μm)
was performed.
Copy number, methylation and expression analyses
Copy number analysis
Experiments were performed according to standard pro-
tocols for Affymetrix Human SNP Assay 6.0 arrays
(Affymetrix Santa Clara, CA, USA). Genomic DNA sam-
ples from sporadic primary clear-cell RCC tumours were
studied. Genotype and copy number analyses were
performed using Affymetrix Genotyping Console version
4.0 with the default settings and the HapMap270 refer-
ence model file supplied by Affymetrix. The quality con-
trol (QC) call rates ranged from 84.9 to 97.5%. Probe
set-level log2 ratios relative to the median of the 270
hapmap reference samples were exported from Genotyp-
ing Console. Data within copy number variation regions
(Affymetrix Genome-Wide Human SNP Array 6.0 An-
notations release 29, July 2009) and on X and Y chromo-
somes were removed. Autosomal log2 ratios were
centred to a median of zero and segmented using GLAD
(Hupe et al., 2004) with the HaarSeg algorithm [40]. As
described previously [41], GISTIC analysis [42] was
performed to identify regions of significant copy number
gain and loss using the GenePattern public server [43]
with the default settings of amplifications threshold of
0.1, deletions threshold of 0.1, join segment size of 4 and
qv threshold of 0.25. SNP, gene, and cytogenetic band lo-
cations were based on the hg18 (March 2006) genome
build (http://genome.ucsc.edu).
Cell line methylation profiling
The cell line DNA from all 15 RCC cell lines was
assayed using the Illumina Goldengate Methylation
Cancer Panel BeadChips (Illumina, San Diego, Ca, USA)
as described previously (for a set of primary RCC) [38].
Within this publication three methylated genes had been
selected and assessed by direct bisulphite sequencing
in several cell lines. The direct bisulphite sequencing
demonstrated a high degree of correlation with the
GoldenGate array (McNemar test, P = 1.0).
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The tumour DNA from the cohort of thirty-eight spor-
adic renal cell carcinoma patients (a single tumour
sample was run twice as a test for reproducibility) and
the normal kidney DNA from nine non-cancerous
kidneys had been assayed using the Illumina Infinium
HumanMethylation27 BeadChips (Illumina). Initial analysis
of these data and its confirmation has been previously
published [19].
Cell line expression profiling
Eleven RCC cell lines (SKRC18, SKRC39, SKRC45,
SKRC47, SKRC54, RCC4, 786-O, KTCL26, UMRC2,
UMRC3 and CAKI-1) had been treated with or without
5-aza-2′-deoxycytidine treatment for five days and the
resulting sets of mRNA had been assayed using the
Affymetrix HG-U133plus2 Genechip arrays (Affymetrix)
as reported previously [2].
mRNA expression analysis of selected candidate genes
One microgram of total kidney tumour or kidney cell
line RNA was converted to cDNA using Superscript III
(Invitrogen) and random hexamer primers (Fermentas
UK, York, UK). RT-PCR primers were designed for each
gene, such that the primers were always positioned in
different exons and had a 56°C annealing temperature.
RT-PCR was performed using a touchdown PCR pro-
gram with five cycles lowered 1°C per cycle down from
61°C to 57°C followed by a further 35 cycles with a final
annealing temperature of 56°C. Primer details are avail-
able on request. Expression of mRNA was graded as ei-
ther lost (no band was observed), downregulated
(obvious loss) or expressed (no obvious loss).
The cancer genome atlas (TCGA - http://cancergenome.
nih.gov/) data
Data were retrieved from the Cancer Genome Atlas using
the TCGA data portal to download the clinical data and
Infinium Methylation27 data for the 199 tumour and asso-
ciated tumour normal samples for which the Infinium
Methylation27 arrays had been performed in the TCGA
KIRC project. This comprised the following records:
TCGA-A3-3306 → 3362 (n = 34), TCGA-B0-3306 →
3362 (n = 6), TCGA-B0-5075 → 5088 (n = 6), TCGA-
B2-3923→ 4102 (n = 5), TCGA-B8-4143→ 4154 (n = 2),
TCGA-BP-4162→ 4167 (n = 5), TCGA-BP-4158→ 4777
(n = 50), TCGA-BP-4781 → 4807 (n = 11), TCGA-BP-
4959 → 5009 (n = 39), TCGA-CJ-4634 → 4644 (n = 9),
TCGA-CJ-4635 → 4895 (n = 24), TCGA-CJ-4899 → 4900
(n = 2) and TCGA-CZ-4854 → 4862 (n = 6). Once
downloaded, a methylation difference value for each probe
in each tumour was calculated as the tumour β-value
minus the associated normal β-value. These values wereused to assess methylation with a value of +0.3 or greater
being considered positive for aberrant hypermethylation.
Additional files
Additional file 1: Table S1. Previously published common deletions
and amplifications/duplications associated with renal cell carcinoma
(RCC).
Additional file 2: Figure S1. A-D. Schematics of the deleted
chromosomes 1, 3p, 14q, 6 and 9. The methylation levels for the selected
genes in the 38 sporadic renal cell carcinomas (RCCs) are represented by
green ovals for no significant methylation or yellow (β-values ≥0.33) and
red (β-values ≥0.4) ovals for positive levels of hypermethylation. The
methylation levels for the nine normal kidneys are represented by green
ovals for no methylation (β-values <0.25). The degree of re-expression
after 5′-aza treatment in the 11 RCC cell lines is represented by green
ovals for no significant increase/change or yellow ovals for a positive
increase (4-fold or greater) and red ovals for a highly positive increase
(8-fold or greater). Other genes of interest were mapped to the
chromosome, with black arrows representing known hypermethylated
RCC-associated genes and blue arrows representing genes known to be
mutated in RCC. The blue star indicates the gene is both mutated and
hypermethylated.
Additional file 3: Figure S2. Schematics of the Amplified/Duplicated
Chromosomes 7, 5q and 20. The methylation levels for the selected
genes in the 38 sporadic renal cell carcinomas (RCCs) are represented by
green ovals for no significant methylation or yellow (β-values ≥0.33) and
red (β-values ≥0.4) ovals for positive levels of hypermethylation. The
methylation levels for the nine normal kidneys are represented by green
ovals for no methylation (β-values <0.25). The degree of re-expression
after 5′-aza treatment in the 11 RCC cell lines is represented by green
ovals for no significant increase/change or yellow ovals for a positive
increase (4-fold or greater) and red ovals for a highly positive increase
(8-fold or greater). Other genes of interest were mapped to the
chromosome, with red arrows representing oncogenes, black arrows
representing known hypermethylated RCC-associated genes and blue
arrows representing genes known to be mutated in RCC.
Additional file 4: Figure S3. Assessment of selected methylated
Infinium Methylation27 probes in the Cancer Genome Atlas (TCGA)
tumour and associated normal pairs. These in-scale diagrams map the
position of the Infinium Methylation27 microarray probes for two of the
five selected genes, AEBP1 and TMEM74, in relation to their CpG island
and first exon. The probes selected for by this analysis are coloured red.
For each probe there is a graph of the average β-values for both the
tumour and the associated normal with the 199 tumour/associated
normal TCGA samples split into those designated methylated or
unmethylated. Methylated samples were defined as having an increase in
β-value of 0.3 or greater within the tumour compared to the associated
normal. The number and percentage of methylated and unmethylated
samples are shown, with those demonstrating significant tumour-specific
methylation coloured in red.
Additional file 5: Table S2. Methylation and clinical data for the 199
Cancer Genome Atlas (TCGA) tumour and associated normal samples.
Additional file 6: Figure S4. Additional Kaplan-Meier survival curves for
the Cancer Genome Atlas (TCGA) samples dependent on the methylation
of the different selected gene probes. These Kaplan-Meier survival curves
demonstrate the difference in survival between methylated and
unmethylated tumours for individual gene probes for AEBP1 and TMEM74
(A) and for methylation of either four or more or two or more of the five
selected gene probes (B). All Kaplan-Meier survival curves were
calculated using MedCalc software (http://www.medcalc.org/).
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